# Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer

> **NCT03649945** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Guangxi Medical University** · enrollment: 186 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Nedaplatin
- **DRUG:** Endostar

## Key facts

- **NCT ID:** NCT03649945
- **Lead sponsor:** First Affiliated Hospital of Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11
- **Primary completion:** 2020-11
- **Final completion:** 2021-05
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2018-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03649945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03649945, "Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03649945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*